Atlas Trials

Exploration of Dalpiciclib Plus HDACi in HR+/HER2- Advanced Breast Cancer After Failure of CDK4/6 Inhibitor

Clinical trial NCT06556862 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06556862
Sponsor
Beijing 302 Hospital
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HR+/HER2- Advanced Breast Cancer
Start date
2025-10-01
Primary completion
2026-12-31
Enrollment
155

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.